Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

dulaglutide and many others. The research-ready Virtual Registry was built as part of the Helix Research Network (HRN). The cohort consists of whole Exome+ ® sequencing profiles for 15,000 GLP-1 ...

Dulaglutide is marketed by Eli Lilly under the brand name Trulicity for the treatment of type 2 diabetes and is registered for this use in South Africa. It is marketed by Aspen through a distribution ...

and Eli Lilly's Trulicity (dulaglutide). Semaglutide is also being developed as a once-weekly injection that has already been shown to provide good control of blood glucose in phase III trials ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...